MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS
Öz
OBJECTIVE: The monocyte count to HDL-Cholesterol ratio (MHR) was increased in patients with cardiovascular disease and, showed as an indicator of cardiovascular risk factors. Functional adrenal tumor and even nonfunctional adrenal adenomas are associated with an increased risk for cardiovascular disease. This is the first study to evaluate the MHR value in patients with adrenal tumors, and examine its relation with cardiometabolic risk factors.
MATERIAL AND METHODS: Twenty-four patients with functional adrenal tumor (10 Cushing syndrome, 12 pheochromocytoma, and 2 primary hyperaldosteronism), patients with non-functional adrenal adenoma (n=33) and, control subjects (n=50) were included. Anthropometric, hormonal and biochemical results, lipid panel, fasting plasma glucose (FPG), blood pressure (BP), blood cell counts, high-sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (CIMT) were compared.
RESULTS: Mean age (51.14±2.03 vs 54.01±9.37 years), sex distribution (female 66.7 % vs 73.8 %), and body mass index (31.12±3.38 vs 30.46±2.96 kg/m2) were similar between adrenal tumor and control group (respectively, p>0.05). The MHR value was higher in the functional tumor group compared with the non-functional adenoma and control group (13.79±3.14, 10.19±2.84 vs 10.08±1.82, respectively, p<0.05). MHR value was similar between the non-functional adenoma and controls (p>0.05). MHR value was positively correlated with systolic BP (r=0.480, p<0.001), diastolic BP (r=0.452, p<0.001), FPG (r=0.333, p=0.001), hs-CRP (r=0.538, p=0.001) and, urinary normetanephrine concentrations (r=0.302, p=0.043). Functional adrenal tumor with cardiovascular disease had higher MHR value compared with those without cardiovascular disease (14.69±2.67 vs 11.84±2.57, p<0.05).
CONCLUSIONS: The MHR value was increased in patients with functional adrenal tumor; however it did not increase in patients with nonfunctional adenoma. MHR value was correlated with cardio-metabolic risk factors such as FPG, BP, and hs-CRP. The MHR value suggests as a predictive marker for cardiometabolic risk factors in functional adrenal tumors.
Anahtar Kelimeler
Kaynakça
- Prof Dr Deniz Gökalp, Acıbadem Üniversitesi, Endokrinoloji ve MetabolizmaProf Dr Kevser Onbaşı, Kütahya Evliya Çelebi Üniversitesi, Endokrinoloji ve MetabolizmaDoç Dr Göknur Yorulmaz, Eskişehir Osmangazi Üniversitesi, Endokrinoloji ve Metabolizma
Ayrıntılar
Birincil Dil
İngilizce
Konular
Klinik Tıp Bilimleri
Bölüm
Araştırma Makalesi
Yazarlar
Selvihan Beysel
*
0000-0001-6963-1503
Türkiye
Mustafa Çalışkan
0000-0003-0342-571X
Türkiye
Muhammed Kızılgül
Türkiye
Özgür Özçelik
Bu kişi benim
0000-0002-1159-5324
Türkiye
Murat Çilekar
Bu kişi benim
0000-0001-9175-6791
Türkiye
Mustafa Özbek
Bu kişi benim
0000-0003-1125-3823
Türkiye
Erman Çakal
Bu kişi benim
0000-0003-4455-7276
Yayımlanma Tarihi
27 Ağustos 2019
Gönderilme Tarihi
13 Mayıs 2019
Kabul Tarihi
22 Temmuz 2019
Yayımlandığı Sayı
Yıl 2019 Cilt: 20 Sayı: 1
